Association among polymorphisms in the apoptosis-related NKX3-1,
caspase-3, caspase-9, and BCL-2 genes and prostate cancer susceptibility
from 9,706 cases and 12,567 controls
Abstract
Introduction While there is a growing volume of evidence
suggesting that relatively prevalent functional polymorphisms present
within apoptosis-related genes may influence human prostate cancer (PCa)
susceptibility, the clinical relevance of these findings remains
inconclusive. This meta-analysis was thus developed with the goal of
generating more precise estimates of the relationships between
polymorphisms in four apoptosis-associated genes (NKX3‑1, Caspase-3,
Caspase-9, and BCL‑2) and the risk of PCa. Material and methods
The PubMed, Web of Science, Google Scholar, Embase, Cochrane Library,
and SinoMed (CNKI and Wanfang) databases were searched for relevant
studies published through December 20, 2023 using the following
keywords: ‘polymorphism’ or ‘variant’ and ‘carcinoma’ or ‘cancer’ or
‘tumor’ and ‘NKX3-1’, ‘CASP3’ or ‘Caspase-3’, ‘CASP9’ or ‘Caspase-9’,
‘BCL-2’ or ‘B-cell lymphoma’ and ‘prostate cancer’ or ‘PCa’ or ‘prostate
adenocarcinoma’. Results This approach led to the
identification of 22 case-control studies related to the association
between apoptosis-related gene polymorphisms and PCa susceptibility
enrolling 9,706 cases and 12,567 controls. Subsequent analyses revealed
that the NKX3-1 rs2228013, CASP9 rs1052571, and
CASP9 rs4645982 polymorphisms were associated with greater PCa
risk, whereas the CASP3 rs4647603 polymorphism was associated
with a risk reduction. Conclusions These findings provide
strong evidence for the potential contributions of polymorphisms in the
apoptosis-related caspase-3, caspase-9, and NKX3-1 genes in the onset
and progression of PCa.